KLK3 and prostate carcinoma: However, the development of FDA methodology for longitudinal data, with relatively small numbers of measurements per subject and irregularly spaced, is an area of ongoing research [40], and has been used to model trajectories of prostate specific antigen (a biomarker of prostate cancer) [41,42].